David Bellaire

Senior Advisor

Dave is an advisor to Sema4, supporting the leadership team on strategic, organizational, business development, operational, and financial and capital formation matters.  He previously served as the executive chair of Sema4.

Dave is also currently an operating partner and co-investor at Waud Capital Partners where his efforts focus on several portfolio companies within the health and health technology services sector.  He has invested in and served in various governance roles in a number of private and public companies during his career.

Dave was previously a senior partner and director at Bain & Company with leadership responsibility for the health plan, provider, and healthcare technologies and services sectors.  Before that, he served as EVP and COO for NDC Health, SVP at APM/Computer Science Corporation, and CEO of two specialty reinsurers that were sold to an industry consolidator. Dave earlier founded, built, and sold Canada Prosthetics and was a Northwestern University Med School faculty member.

Dave received an MBA. and M.A. degrees with highest honors from Northwestern University.

Rong Chen

SVP, Bioinformatics R&D

Rong Chen, Ph.D., was the Director of the Clinical Genome Informatics Laboratory, and Assistant Professor in the Department of Genetics and Genomic Sciences and Institute of Genomics and Multiscale Biology at Icahn School of Medicine at Mount Sinai. Dr. Chen is an expert on translational bioinformatics and has published more than 80 papers in journals such as Nature Biotechnology and The Lancet. He has developed numerous databases and software tools to interpret genomes to help drive clinical diagnosis, precision medicine, and therapeutic target discovery, including knowledge bases for various clinical genetic testing, VIAS for genetic variant annotation, ClinLabGeneticist for clinical exome sequencing, and ZDOCK, one of most widely-used protein-protein docking programs. Dr. Chen led the Resilience Project, a study designed to identify genetic ‘superheroes’ in more than 589,000 individuals, and a personalized cancer therapy project for precision medicine. He has illustrated the genetic landscapes of parathyroid carcinoma and Cushing’s disease, identified potential therapeutic targets for cardiovascular diseases, and identified diagnostic biomarkers for organ transplant rejection. Dr. Chen also developed novel methods to predict personal risk of disease by integrating genome sequencing, electronic medical records, and environmental factors. He published the first Clinical Assessment of Human Genome and was a leader in the development of the personal genome report. Before joining Mount Sinai, Dr. Chen built and launched the genomic medicine startup company, Personalis. He has also worked at Accelrys/BIOVIA, Quest Diagnostics Nichols Institute, Abgenix/Amgen, and Stanford University. Dr. Chen received his B.S. in Chemical Physics from the University of Science and Technology in China, his M.S. in Structure Biology from Chinese Academy of Sciences, and his Ph.D. in Bioinformatics from Boston University.

Dan Clark

General Counsel

Dan is a mission-driven advocate overseeing all legal and regulatory matters for Sema4. Prior to joining Sema4, Dan practiced with two leading law firms in New York, clerked for Judge Frederic Block in the Eastern District of New York, and helped found a boutique startup law firm. Dan graduated with honors from the University of Michigan School of Law and Pomona College, and he traveled as a Thomas J. Watson Fellow.

James Coffin

President and Chief Operating Officer

James Coffin, Ph.D., also known as Jamie, is a pioneer in the healthcare and life sciences sector.  He recently served as Chief Executive Officer and President at Source Medical Solutions, the #1 provider of practice management and EMR solutions in the Ambulatory Surgical space.  Previously, Jamie was Worldwide Vice President and General Manager at Dell, leading the Global Healthcare Life Science (HCLS) business over a six-year period to become the #1 healthcare IT services company in the world with $3.5b in revenue, and a workforce of ~13,000 people. He pioneered Dell’s efforts to apply leading-edge information technology into areas including EMR, data analytics, high performance and cloud computing, personalized medicine, claims processing, medical imaging, and pharmaceutical and biotech drug discovery. Prior to Dell, he served as Worldwide Vice President of IBM Healthcare and Life Sciences and grew the division to a $6.5b business. He was also a Director at Terascala Inc.

Alan Copperman

Chief Medical Officer – Reproductive Health

Alan B. Copperman, M.D. is the Director of the Division of Reproductive Endocrinology and Infertility and the Vice-Chairman of the Department of Obstetrics, Gynecology and Reproductive Science at The Icahn School of Medicine at Mount Sinai. Dr. Copperman was a co-founder and serves as Medical Director of RMA of New York, one of the largest and most prestigious IVF Centers in the country. He is an experienced and respected clinician, and has a long history of achieving success in treating infertility and in applying fertility preservation technologies. He has published numerous manuscripts and book chapters on reproductive medicine, and has co-authored hundreds of scientific abstracts on infertility, in vitro fertilization, egg freezing, ovum donation, and genetics. Dr. Copperman is frequently quoted in print and digital media, including the Associated Press, Wall Street Journal, U.S. News & World Report, The New York Times, WebMD, SELF, Health.com, Parenting magazine, Parents.com, and Refinery29. He has been featured on local and nationally-televised news shows, including Fox 5 NY Live, CBS This Morning, Huffington Post Live, Anderson Cooper 360, and 20/20. Dr. Copperman was named to New York magazine’s list of Best Doctors sixteen years in a row. He has been recognized annually by Castle Connolly and SuperDocs as one of the top fertility doctors and by his peers and patient advocacy organizations for his commitment to patient-focused and data-driven care.

Lisa Edelmann

Chief Diagnostics Officer

Lisa Edelmann, Ph.D. was the Executive Director of the Mount Sinai Genetic Testing Laboratory and holds the academic title of Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. Dr. Edelmann received her Ph.D. in Molecular Genetics from The Albert Einstein College of Medicine, and is certified in Clinical Molecular Genetics and Clinical Cytogenetics by the American Board of Medical Genetics and Genomics. Her scientific accomplishments include, elucidating the mechanism of chromosome 22q11 rearrangements and involvement in the first molecular sequencing of an entire human chromosome. She has also published extensively on Ashkenazi Jewish genetic disorders and has developed several novel tests, including a test for detection of silent carriers for spinal muscular atrophy, which is being licensed nationwide and abroad. Dr. Edelmann is a nationally recognized expert in population-based carrier screening, high-throughput clinical diagnostic sequencing as well as genomic disorders and clinical interpretation of copy number variation. She is well versed with the regulatory guidelines that govern clinical laboratories and has extensive experience with the process of validating LDTs and bringing them to market.

Glenn Farrell

Chief Marketing Officer and EVP, Research Strategy

Glenn has over 25 years of experience in leading brand and product strategy and driving successful marketing programs at mission-driven companies and organizations in industries ranging from software and biotech to big data and healthcare.

As Chief Marketing Officer at Sema4, Glenn leads our efforts to build brand awareness and preference for Sema4 products and services by crafting the company’s story, narrative, and positioning strategy with key target audiences. He helped create our key brands, from the Sema4 corporate brand to Centrellis™ for our health intelligence platform, Traversa™ for our exome-based genomic platform, and Sema4 Signal™ for our oncology portfolio of products and services.

Glenn also serves as Sema4’s EVP of Research Strategy, with responsibility for driving a holistic, integrated view of Sema4’s research roadmap, aligning the company’s resources on our highest priority initiatives to advance our mission to transform healthcare through data-driven insights.

Prior to Sema4, Glenn was Chief Marketing Officer at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. Previously, he led marketing communications at Pacific Biosciences, where he played an integral role in the company’s successful IPO and rapid scaling of its global marketing and sales. Before PacBio, Glenn led Microsoft’s global brand and marketing strategy team for its flagship Windows products, Server software portfolio, and online services. He collaborated with Microsoft R&D teams to define the value proposition and roadmap for future products.

Glenn earned his B.A. in political science, cum laude, from Yale University.

Krish Ghosh

Chief Analytics Officer

Krish Ghosh, Ph.D., an innovator and strategic thinker, with more than 25 years of experience, has extensive expertise in developing and executing business strategies, and leading cross-functional global teams and programs to drive growth for companies in the pharmaceutical, healthcare, and clinical research organization industries. Krish also has broad experience with the applications of artificial intelligence, machine learning, and natural language processing tools to develop industry leading capabilities in clinical trial management and conduct. At Sema4, he is a mission-driven executive helping to drive the growth of the business through the development of next-generation software products, big data analytics, innovative clinical trial optimization solutions, and by forming strategic partnerships with companies with data, technology and analytical capabilities.

Prior to joining Sema4, Krish successfully led and managed large units across multiple sites and regions at LabCorp/Covance for 13 years. His remit included software development, informatics, big data analytics, portfolio management, resource management, high-end statistics, and clinical trial optimization. Krish created the vision and led the development of several leading differentiators at LabCorp/Covance, optimizing patient recruitment, study design, investigator selection, forecasting, and resource demand and supply management for global trials.

Before that, Krish spent 12 years between Wyeth Pharmaceuticals and Bristol Myers Squibb, where he worked across the entire drug development continuum, including discovery, preclinical, clinical/regulatory, project and portfolio management, resource management and R&D benchmarking. Krish previously spent four years as Assistant Professor at the University of Michigan and the University of Montana, teaching several graduate and undergraduate courses and supervising graduate students.

Krish received his Ph.D. in Statistics and MBA in Finance from Temple University.

Shay Hassidim

Chief Information Security Officer

Shay brings more than two decades of experience of technical management and leadership skills, helping Sema4 implement its information technology and predictive, personalized healthcare platform, as well as various other clinical systems using cloud-based architecture. Shay has in-depth technical experience with diverse technologies, including cloud computing, in-memory computing, and big data. Shay has been involved with large scale projects in different verticals working with Fortune 500 multinational global companies, including financial services, telecom, healthcare, e-commerce, travel, logistics, homeland security, and more. Prior to joining Sema4, Shay was part of the GigaSpaces XAP and Cloudify product leadership teams from their inception, overseeing the technical activities of the U.S. operations, serving as Deputy CTO Distinguished engineer, and escorting the pre-sale and post-sale activities. Prior to GigaSpaces, Shay served as a Lead Architect and Technical Manager at Versant ODBMS, and VMDB Database Tools Lead Architect at Sirius Technologies. Shay holds a B.Sc. in Electrical and Computer Engineering from Ben-Gurion University in the Negev.

Ke Hao

Head of Statistical Genomics

Ke Hao, ScD, Head of Statistical Genomics at Sema4, leads the development of prediction models for complex human diseases by integrating genetic predisposition and environmental / life style factors. Dr. Hao is also an Associate Professor at the Icahn School of Medicine at Mount Sinai in the Department of Genetics and Genomic Sciences and Institute for Data Science and Genomic Technology. His main focus is on discovering genetic and environmental basis of human diseases comprised of leading-edge research in translational statistical genetics, and applying computational algorithms, e.g. polygenic risk score and machine learning approaches, to mine massive datasets and deliver clinical utility and insights.

Dr. Hao was trained in statistical genetics and environment health with a BSc at Tsinghua University, China, and a ScD at Harvard University School of Public Health. Dr. Hao has extensive experiences working in both biotech and pharmaceutical companies (Affymetrix, Inc, and Merck & CO) on high dimensional ‘omics data modeling and product development. He is also funded by grants from NIH and other agencies, and developed novel methods that are widely used in statistical genomics and environment health research. He is one of the pioneers studying the role of genetics and environment exposure during early life, including in utero period, and the health consequences. Dr. Hao developed a hardware/software system, Bio3Air, to long-term measure ambient pollutant exposure at individual level, which has been deployed in multiple human studies. Further, he led the first study demonstrating the influence of air pollution on human respiratory tract microbiome and health outcomes. Dr. Hao has published extensively in the fields of statistical genomics, epidemiology and environmental health, with more than 100 peer-reviewed papers in journals including Science, Nature Genetics, Nature Neuroscience and Nature Communications.

Li Li

VP, Clinical Informatics

Li Li, M.D., is Vice President of Clinical Informatics at Sema4, leading the development of a common data model for electronic medical records (EMR), driving the development and improvement of clinical applications for reproductive diseases, newborn health, and deep imaging learning and aiming to advance novel diagnostics, therapeutics, and insights into both diseases and wellness.

Also, Dr. Li is an Assistant Professor at the Icahn School of Medicine at Mount Sinai in the Department of Genetics and Genomic Sciences and the Institute for Next Generation of Healthcare.

Dr. Li was trained as both a physician and bioinformatician, with an M.D. in Clinical Medicine from the Dalian Medical School in China and an M.S. in Bioinformatics from Boston University, and has over 16 years of experience in both industry (Quest Diagnostics) and academia (Stanford University, UCSD) with a focus on EMR and multi-omics data. At graduate school, she developed RDOCK, which has become one of the most widely-used protein-protein docking software programs. She successfully established the precision medicine groundwork including deep phenotyping of Lyme Disease, categorizing subtypes of type 2 diabetes for treatment stratification rather than one size fits all model, developing deep machine learning algorithms to improve disease prognostics, identifying key clinical risk factors from EMR to improve quality of care for patients, and developing biomarker diagnostic assays for acute rejection and tolerance of kidney transplantation. She has received four Young Investigator Awards from the American Society of Transplantation and the Transplantation Society. Her three international patents led to the creation of the start-up company Organ-I Inc., acquired by IMMUCOR Inc., and one patent of identification of drug targets to treat kidney fibrosis and chronic graft injury. Dr. Li has published extensively in the fields of precision medicine, bioinformatics, and clinical bioinformatics, with more than 75 peer-reviewed papers in journals including Nature Biotechnology, Science Translational Medicine, and PNAS.

Bobbie Lyons

VP, HR Operations

Bobbie Lyons is a seasoned Human Resources professional whose career spans leadership roles in the real estate, public relations, consulting, and entertainment industries. Before joining Sema4, she was the Senior Vice President of Human Resources at Rouse Properties, Inc. where she developed an original human resources function and proceeded to drive all human capital initiatives for the company. Bobbie has a track record of working with start up organizations having installed human resources functions in 3 such companies. She is a past Board Member of the Society for Human Resources Management, and has been an adjunct instructor at Sacred Heart and New York Universities. She is a certified administrator of the Occupational Personality Questionnaire Assessment Instrument (OPQ).

Murali Mani

Chief Compliance Officer

At Sema4, Murali is responsible for governance, risk and compliance, and ensuring trust and transparency with patients, regulators, clients, institutional review boards, and business partners. He drives policies and procedures, and internal and external audits to comply with key regulations, standards, and certifications. Prior to joining Sema4 in September 2020, Murali was the Director of Compliance at IBM Watson Health where he built a quality and compliance program for an extensive portfolio of SaaS and on-premises health products and services in more than 10 countries. He also established data governance frameworks and workflows for health data analytics on datasets with more than 300 million patients. Before joining Watson Health, Murali was the Senior Privacy Officer for Philips Group Innovation, with responsibility for overseeing several hundred human subject studies across approximately a dozen countries. Murali has a Ph.D. in Mechanical Engineering from Northwestern University and holds Certified Information Privacy Professional (CIPP) and Project Management Professional (PMP) credentials from the International Association of Privacy Professionals and Project Management Institute, respectively.

Sheila Moran

SVP, Solutions Sales

Sheila Moran has over two decades of experience building, coaching, and leading high performance, consultative sales teams in the Healthcare Industry. Prior to Sema4 she was VP of Sales for the Therapy division of Source Medical leading the team to double their business in Software and Revenue Cycle Management culminating in the successful sale of the business. She held a variety of leadership positions domestically and globally over a 20 year tenure at IBM where she led teams in complex solution sales to the Healthcare Provider, Payer, and Pharma Industries including Data Mining and Analytics, Clinical Genomics, Research Computing Solutions, and Commercial Production Systems. Sheila has held dual roles in operations, marketing and product development enabling her to bring a deeper level of experience to growing emerging businesses as well as driving new growth in established businesses. Sheila earned a BS in Chemical Engineering from the Illinois Institute of Technology in Chicago.

Thomas Neyarapally

Chief Commercial Officer

Thomas A. Neyarapally was previously a member of the founding team and Executive Vice President, Corporate Development at the healthcare analytics company GNS Healthcare, where he led the expansion of GNS’ business from systems biology into the commercial groups within pharma as well as payers and providers, and secured the company’s core intellectual property. Tom also helped launch Cibo Technologies, an agriculture predictive modeling startup, as Chief Operating Officer, and served as a corporate and intellectual property lawyer at Chadbourne & Parke LLP and Frommer Lawrence & Haug LLP. He started his career as a pharmaceuticals analyst at the management consulting firm Arthur D. Little. Tom received his degree in chemical engineering, cum laude and as an Honors Scholar, from the University of Connecticut, and JD and MBA degrees from Cornell University.

William Oh

Chief Medical Science Officer

William K. Oh, M.D., is an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers.

Before joining Sema4, Dr. Oh served as Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. He was also the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at Mount Sinai. In addition to his current role at Sema4, Dr. Oh continues to care for his patients as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai, where he has been recognized by New York Magazine as a Best Doctor for the past decade.

Prior to joining Mount Sinai, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. In addition to his roles as a widely respected clinician, researcher, and principal investigator of multiple clinical trials, Dr. Oh developed large clinical databases and specimen biorepositories for genitourinary cancers at both the Harvard’s Dana-Farber Cancer Institute and Mount Sinai.

Dr. Oh has authored more than 300 articles, reviews, and book chapters related to prostate, renal, bladder, and testicular cancers.  He has also edited three books on prostate cancer, and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer.

Dr. Oh is a graduate of Yale College and New York University School of Medicine, and completed his training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

Qi Pan

SVP & GM, Research Business Unit

Qi Pan, Ph.D., has over 14 years of experience in biotech and pharmaceutical R&D and gained in-depth knowledge on oncology and biotherapeutic drug discovery and development. Prior to Sema4, she was VP of R&D at Legend Biotech, a leading biotech company in the development of BCMA CAR-T therapy to treat multiple myeloma. At Legend Biotech, Qi led a team of scientists working on an innovative CAR-T preclinical research portfolio aiming to cure both hematological and solid tumors, and she was also responsible for setting the company’s cancer immunotherapy R&D strategies. Previously, Qi worked in pharmaceutical companies such as Genentech and Boehringer Ingelheim and had led project teams to deliver multiple high quality biotherapeutic molecules from research to clinical development, including cancer indications and auto-immune indications. At Boehringer Ingelheim, Qi was also responsible for leading exploratory biotherapeutic portfolio for Tumor Immunology and Immune Modulation. Qi received her Ph.D. from Harvard University in the field of molecular and cellular biology.

Lauren Peters

Head of Disease Discovery

As Head of Disease Discovery at Sema4, Lauren Peters, Ph.D. is designing next generation in silico models of disease to uncover patient data driven mechanisms of disease pathogenesis and identification of novel patient subsets, biomarkers and approaches to therapeutic discovery. Dr. Peters is also an Assistant Professor in the Department of Genetics & Genomic Sciences and the Icahn Institute for Data Science & Genomic Technology at the Icahn School of Medicine at Mount Sinai where she has focused on the analysis and experimental validation of computational models of disease in collaboration with Janssen and led numerous publications including in Nature Genetics, Gastroenterology and Nature Immunology. Prior to completing her Ph.D. in Biomedical Science at the Icahn School of Medicine at Mount Sinai in Immunology and Genetics, Dr. Peters was a scientist in oncology therapeutic discovery in the Cell Biology group in R&D at Imclone Systems, Eli Lilly, worked in business development at Regeneron and in Genetics and Development at Columbia University, where she earned a M.A. in Biotechnology. Dr. Peters also has worked in Information Technology at Barclays and management consulting at Kaiser Associates; advising Fortune 100 clients in the pharmaceutical, technology and other industries on business strategy. She holds a BA in International Relations with a concentration in Economics from Boston University.

Matt Phillips

SVP, Business Development

Prior to joining Sema4, Matt was Senior Vice President of Business Development of Surgical Information Systems (SIS) and assisted in transitioning the partner programs he had built prior to the SIS acquisition of SourceMed, a PE-backed healthcare IT and services company focused on practice management, revenue cycle and clinical documentation of outpatient clinics.  Through the partner program, Matt drove innovation and positive growth in the legacy SourceMed business that supported the SIS transaction.  Prior to SourceMed, Matt led many Business Development activities over 15 years at Dell, Inc. primarily serving the Healthcare and Life Sciences markets in solution creation, partnerships and incubation of net new technologies.  Matt is recognized as a subject matter expert in patient and provider engagement and has built, led, and launched many net new businesses to market all focused on delivering better healthcare outcomes.  Prior to Dell, Matt owned a small business in the restaurant industry.

Tony Prentice

Chief Product Officer

Tony Prentice is an innovative product developer, strategist, and leader. Tony was the Vice President of Mobile Payments at American Express, where he built the organization for new commerce products, applications, and mobile wallets. The team delivered enterprise strategy and products including Apple Pay, Android Pay, and the Amex app. Previously he had various product management roles at American Express including Gold Card, Starwood, Hilton and Blue cards. Prior to Amex, Tony had various product, general manager and engineering roles at Starbucks, McKinsey & Co and GE.

Isaac Ro

Chief Financial Officer

Isaac Ro has 20 years of financial leadership and experience, with a strong focus on the medical technology and life sciences space. As Chief Financial Officer (CFO) at Sema4, Isaac is responsible for leading all aspects of financial strategy, management, and planning.

Prior to joining Sema4, Isaac served as CFO of Thrive Earlier Detection Corp., a company dedicated to incorporating earlier detection of cancer into routine medical care. In this capacity, he led the sale of Thrive to Exact Sciences Corp. (Nasdaq: EXAS) for $2.15 billion after rapidly scaling the company and raising $257 million in a Series B financing.

Before Thrive, Isaac led the U.S. Medical Technology team at Goldman Sachs where he covered the Life Science Tools, Diagnostics, and Medical Technology sectors. He also held a similar role at SVB Leerink. His career as an equity analyst spanned 16 years, over 60 publicly traded companies, and numerous IPOs and equity financing transactions.

Isaac holds a B.A. in History and was pre-med at Middlebury College.

Kareem Saad

Chief Business Officer

As Chief Business Officer at Sema4, Kareem Saad is responsible for driving corporate strategy, corporate development, and emerging business initiatives to further accelerate the company’s growth. Kareem has also served as Chief Strategy Officer at Sema4.

Prior to joining Sema4, Kareem was President and Chief Operating Officer at Apervita, Inc., overseeing its transformation to a product- and value-based care and quality measurement technology company. Kareem previously served as Chief Commercial Officer/EVP of Strategy and Business Development at SourceMed, a PE-backed healthcare IT and services company focused on delivering practice management technology solutions to the outpatient market, where he led a series of transactions that culminated in the sale and merger of the company with Surgical Information Systems.

Kareem also served as a Director in Dell’s Healthcare and Life Sciences division where he was responsible for managing a $180 million healthcare partner program. Before that, he held a number of executive roles in biotech and healthcare technology startups as well as leading the Information Based Medicine Commercial Group at IBM’s Healthcare Life Sciences group helping grow that business to $100 million in less than five years.

Kareem holds a BSc in Biochemistry and Molecular Biology with a minor in Computer Science from the University of British Columbia and an MBA with a concentration in Economics and Finance from the University of Chicago.

Eric Schadt

Founder and Chief Executive Officer

Eric Schadt, Ph.D., is founder and CEO of Sema4, a patient-centered health intelligence company built on the idea that more information, deeper analysis, and increased. longitudinal engagement of patients will improve the diagnosis, treatment, and prevention of disease. Eric has overseen rapid growth at Sema4 since the company was founded in 2017, driven by the company’s dedication to advancing healthcare through data-driven insights.

Eric is a world-renowned expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 400 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with Centrellis™, Sema4’s innovative health intelligence platform, Eric is using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Eric also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at Icahn School of Medicine at Mount Sinai. He was previously Founding Director of Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences.

Eric earned his Ph.D. from the University of California, Los Angeles, his M.A. from the University of California, Davis, and his B.S. from California Polytechnic State University-San Luis Obispo.

Robert Sebra

VP of Technology Development

Robert Sebra, Ph.D., leads Technology Development at Sema4 with a focus on technology adoption, and research and development to create high-throughput diagnostics and innovative IP. Dr. Sebra has vast experience in molecular, biochemical, and sequencing technology including surface bioconjugation techniques, lab-on-a-chip platforms, active biomaterials, single-molecule platforms, and the integration of bulk and single cell sequencing technologies for basic science and clinically driven applications. He is a leading expert in sequencing platforms and a pioneer in new approaches for single molecule and single cell assay development. Dr. Sebra has published more than 50 papers in top tier journals, including Science, Cell, Nature, NEJM, and Cancer Discovery, and his work has led to multiple issued patents. Dr. Sebra will continue as the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology and an Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai in New York. Since establishing a team at Icahn School of Medicine at Mount Sinai, Dr. Sebra has applied WGS and targeted genomics approach toward a better understanding of genomic variation for higher resolution human disease diagnostics in cancer and inherited disease, alongside infectious disease surveillance using both long- and short-read sequencing techniques. Prior to his work at Sinai, Dr. Sebra was involved in research and development contributing to single molecule real-time long read sequencing technology and applications at Pacific Biosciences after receiving his Ph.D. in Chemical and Biological Engineering at University of Colorado, Boulder.

Karen White

Chief People Officer

Karen has more than 25 years of experience in strategy, organization, and leadership development, and human resources, including a decade in the healthcare and life sciences industry. At Sema4, she is responsible for all elements of the people strategy, with a particular focus on talent, diversity, culture, and employee experience.

Prior to joining Sema4 in September 2020, Karen was Vice President of Human Resources for Commercial Solutions at Syneos Health, a fully integrated biopharmaceutical solutions organization. Among other things, she led the Global Commercial team through a merger and transition to processes in a public company. Prior to joining Syneos Health, Ms. White held senior HR roles at other companies in the healthcare space, including inVentiv Health Consulting and Memorial Sloan Kettering Cancer Center. Before that, Ms. White held positions at large global organizations such as Goldman Sachs, IBM, and PricewaterhouseCoopers.

Karen has a collaborative and flexible approach to designing and delivering high performance solutions. She is a certified executive coach who has designed and implemented groundbreaking development programs to stimulate leadership and improve cultures, and is certified in an array of assessment instruments. Karen has two children and is also an active member of the Leukemia & Lymphoma Society. She earned her MBA from The George Washington University and her B.A. from Hobart and William Smith Colleges.

Bridget Winders

SVP & GM, Women’s Health

Bridget Winders has over 20 years of expertise in business and go-to-market strategy, services and sales in industries ranging from healthcare, education, government, and financial.  Prior to Sema4, she was Vice President of the Central and Pacific Northwest region for Dell | EMC and Dell’s Healthcare and Life Sciences organization focused on delivering quality outcomes with data analytics and broad IT solutions.  As an early employee of Gateway Computers, Bridget led sales teams through explosive growth amid the company’s evolution from start-up to key player in the burgeoning computer market. In various leadership roles, she has built diverse, multidisciplinary teams that afforded the business effective operations through collaboration.

Jun Zhu

Head of Data Sciences

Jun Zhu, PhD is a professor in Department of Genetics and Genomic Sciences and a member of Institute of Genomics and Multiscale Biology. Dr. Zhu was trained in both computer science and biomedical science. His research focuses on methodology development for integrating diverse omics data (e.g. genetic, genomic, transcriptomic, proteomic data and etc.) into probabilistic graphic networks. His work has been supported by multiple NIH grants and his methods have been used to identify novel drug targets and elucidate complex human disease mechanisms, which have resulted in publications in top journals in Nature, Nature Genetics, and Cell and multiple patents. Dr. Zhu has extensive experiences working in both biotech and pharmaceutical companies (Amgen, Inc, and Rosetta/Merck & CO, Inc) and academia (Sage Bionetworks, Fred Hutchinson Cancer Research Center, and Icahn School of Medicine at Mount Sinai).

Michelle Zimmerman

SVP & GM, Oncology Solutions

Michelle is a seasoned healthcare executive with expertise building and growing companies in digital health, health services, health insurance, and health information. Prior to joining Sema4, Michelle served in leadership positions across a number of healthcare growth companies. She served as SVP, US Operations & Business Development for Mavencare, a venture-backed home health company and as Chief Innovation Officer at AlphaCare, a managed care plan acquired by Magellan Health. She was a founding member of Aetna’s commercial innovation team where she built and incubated healthcare start-ups backed by Aetna . Michelle began her career in management consulting with the Boston Consulting Group and in corporate law with Paul Weiss, Rifkind, Wharton & Garrison. Michelle also has experience on the policy side of healthcare and has published on the topic of resource allocation decision making. Michelle holds an Honors Bachelors of Arts in Economics and Criminology, and JD and MBA from the University of Toronto.

David Zirl

SVP & GM, Emerging Business and COVID-19

David Zirl has spent his career designing and implementing go-to-market strategies to help customers take advantage of innovative IT and business solutions that drive changes and transformations in life sciences R&D, healthcare delivery and medical claims processing. He most recently was the Chief Sales Officer for EMSI, a mobile health information collection company. He was an SVP for Xerox Government Healthcare, where his teams delivered Medicaid claims processing and Eligibility services to 10 western states. He previously led solution sales, business development and marketing teams for Dell, IBM, Silicon Graphics and Kendall Square Research. David earned a PhD in ceramic engineering from Rutgers University.